Review Article | Published:

Advances in the production of human therapeutic proteins in yeasts and filamentous fungi

Nature Biotechnology volume 22, pages 14091414 (2004) | Download Citation

Subjects

  • A Corrigendum to this article was published on 01 December 2004

Abstract

Yeast and fungal protein expression systems are used for the production of many industrially relevant enzymes, and are widely used by the research community to produce proteins that cannot be actively expressed in Escherichia coli or require glycosylation for proper folding and biological activity. However, for the production of therapeutic glycoproteins intended for use in humans, yeasts have been less useful because of their inability to modify proteins with human glycosylation structures. Yeast glycosylation is of the high-mannose type, which confers a short in vivo half-life to the protein and may render it less efficacious or even immunogenic. Several ways of humanizing yeast-derived glycoproteins have been tried, including enzymatically modifying proteins in vitro and modulating host glycosylation pathways in vivo. Recent advances in the glycoengineering of yeasts and the expression of therapeutic glycoproteins in humanized yeasts have shown significant promise, and are challenging the current dominance of therapeutic protein production based on mammalian cell culture.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Biopharmaceutical Benchmarks—2003. Nat. Biotechnol. 21, 865–870 (2003).

  2. 2.

    , , , , & Filamentous fungi as cell factories for heterologous protein production. Trends Biotechnol. 20, 200–206 (2002)

  3. 3.

    , , , & High-yield secretion of recombinant gelatins by Pichia pastoris. Yeast 15, 1087–1096 (1999).

  4. 4.

    & Cholesterol drugs dominate. MedAdNews 22, 42–57 (2003).

  5. 5.

    , , & The role of carbohydrate in the assembly and function of polymeric IgG. Mol Immunol. 37, 1081–1090 (2000).

  6. 6.

    , & Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. The Lancet, 348, 1555–1559 (1996).

  7. 7.

    et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glycocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122, 33–39 (1995).

  8. 8.

    , , , & Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells. Glyconj. J. 16, 81–97 (1999).

  9. 9.

    , , & N-glycosylation/deglycosylation as a mechanism for the post-translational modification/remodification of proteins. Glycoconj J. 12, 189–193 (1995).

  10. 10.

    et al. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA. 86, 7819–7822 (1989).

  11. 11.

    et al. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br. J. Haematol. 121, 511–526 (2003).

  12. 12.

    et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. USA 100, 6741–6746 (2003). Erratum in: Proc. Natl. Acad. Sci. USA 100, 9102 (2003).

  13. 13.

    et al. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 93, 2807–2816 (1999).

  14. 14.

    , , , & Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176–180 (1999).

  15. 15.

    Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting. Glycobiology 9, 841–850 (1999).

  16. 16.

    Metabolic engineering glycosylation: biotechnology's challenge to the glycobiologist in the next millennium. in Part IV Biology of Saccharides. (eds. Ernst, B., Hart, G. & Sinay, P.) 1043–1064 (VCH-Wiley, New York, 2001).

  17. 17.

    , , & Recombinant protein expression in Pichia pastoris. Mol. Biotechnol. 16, 23–52 (2000).

  18. 18.

    et al. Expression and characterization of recombinant human antithrombin III in Pichia pastoris. Protein Expr. Purif. 23, 55–65 (2001).

  19. 19.

    et al. Characterization of humanized antibodies secreted by Aspergillus niger. Appl. Environ. Microbiol. 70, 2567–2576 (2004).

  20. 20.

    , , , & High-level secretory expression of immunologically active intact antibody from the yeast P. pastoris. Biotechnol. Letters, 21, 561–567 (1999).

  21. 21.

    & Methods for modifying carbohydrate moieties. US patent 5,834,251 (Dec. 30, 1994).

  22. 22.

    et al. In vitro conversion of the carbohydrate moiety of fungal glycoproteins to mammalian-type oligosaccharides. Eur. J. Biochem. 249, 701–707 (1997).

  23. 23.

    & Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631–664 (1985).

  24. 24.

    , & Control of glycoprotein synthesis. The use of oligosaccharide substrates and HPLC to study the sequential pathway for N-acetylglucosaminyltransferases I, II, III, IV, V and VI in the biosynthesis of highly branched N-glycans by hen oviduct membranes. Biochem. Cell Biol. 66, 1134–1151 (1988).

  25. 25.

    & Biochemistry, molecular biology and genetics of oligosaccharyltransferase. FASEB J. 10, 849–858 (1996).

  26. 26.

    & Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim. Biophys. Acta 1426, 227–237 (1999).

  27. 27.

    , , & Alpha-D-mannosidases of rat liver Golgi membranes. Mannosidase II is the GlcNAcMan5-cleaving enzyme in glycoprotein biosynthesis and mannosidases IA and IB are the enzymes converting Man9 precursors to Man5 intermediates. J. Biol. Chem. 257, 3660–3668 (1982).

  28. 28.

    , , & Insertion into Aspergillus nidulans of functional UDP-GlcNAc: α3-D-mannoside β-1,2-N-acetyl-glucosaminyltransferase I, the enzyme catalyzing the first committed step from oligomannose to hybrid and complex N-glycans. Glycoconj. J. 12, 360–370 (1995).

  29. 29.

    , , , & Modification of the protein glycosylation pathway in the methylotrophic yeast, Pichia pastoris. Biotechnol. Letters 20, 1171–1177 (1998).

  30. 30.

    et al. Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae. J. Biol. Chem. 273, 26298–26304 (1998).

  31. 31.

    et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl. Acad. Sci. USA 100, 5022–5027 (2003).

  32. 32.

    , & Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins. US Patent Appl. No. 60/532,461 (December 23, 2003).

  33. 33.

    et al. In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris. Appl Environ Microbiol. 70, 2639–2646 (2004).

  34. 34.

    et al. Production of complex human glycoproteins in yeast. Science, 301, 1244–1246 (2003).

  35. 35.

    et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 14, 757–766 (2004).

Download references

Author information

Affiliations

  1. Thayer School of Engineering, the Department of Biological Sciences and the Department of Chemistry, Dartmouth College, Hanover, New Hampshire 03755, USA and GlycoFi Inc., 21 Lafayette Street, Lebanon, New Hampshire 03766, USA.

    • Tillman U Gerngross

Authors

  1. Search for Tillman U Gerngross in:

Competing interests

T.U.G. has equity exceeding 5% in a company (GlycoFi) that develops yeast-based protein expression systems.

Corresponding author

Correspondence to Tillman U Gerngross.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1028

Further reading